⚠️Educational purposes only. Not medical advice. Consult a licensed provider before use. Many peptides are research-grade compounds not FDA-approved. Verify legal status in your jurisdiction.
← Back to library
Larazotide
Larazotide Acetate (AT-1001)
ModerateResearch Grade
A tight-junction regulator that reduces intestinal permeability (leaky gut) — the only peptide in Phase 3 trials specifically targeting gut barrier function.
Mechanism of action
Tight junction stabilization, zonulin pathway inhibition, intestinal permeability reduction
Primary benefits
- ✓Leaky gut repair
- ✓Celiac symptom reduction
- ✓Intestinal barrier protection
- ✓Inflammatory bowel support
Dosing
Beginner
0.5 mg 3x daily
Intermediate
1 mg 3x daily
Advanced
2 mg 3x daily
Frequency: 3x daily with meals
Timing: With each meal
Route: Oral
Cycling protocol
Duration
12-26 weeks
Pattern
Daily with meals
Break after
4-8 weeks
Important warnings
- ⚠️Phase 3 trials ongoing — not yet FDA-approved
- ⚠️Best studied in celiac disease
- ⚠️Use under GI specialist supervision